Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06566079 · ClinicalTrials.gov registry record · Phase 1

Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors

A Phase 1 study of Advanced Solid Tumor and Malignant Mesothelioma, sponsored by InSilico Medicine Hong Kong Limited.

Recruiting
Registry status
Phase 1
Development phase
100
Enrollment target
10
Study locations

NCT06566079 is a Phase 1 study of Advanced Solid Tumor and Malignant Mesothelioma that is actively recruiting participants, run by InSilico Medicine Hong Kong Limited. The registered enrollment target is 100 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (48% lower). The trial reports 10 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06566079, a Phase 1 study of Advanced Solid Tumor and Malignant Mesothelioma, is actively recruiting participants, sponsored by InSilico Medicine Hong Kong Limited.

RECRUITING
Registry status
Phase 1
Development phase
100 participants
Enrollment target
10
Study locations

Study Summary

This is a Phase 1, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with advanced or metastatic malignant mesothelioma or other solid tumors. The study consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2).

Conditions Studied

Advanced Solid Tumor Malignant Mesothelioma Metastatic Malignant Solid Tumor

Interventions

  • DRUG ISM6331

Study Locations (10)

Other

  • Cancer Hospital Chinese Academy of Medical Sciences - Beijing
  • Sun Yat-Sen University Cancer Center - Guangzhou

Colorado

  • Sarah Cannon Research Institute at HealthONE - Denver

Illinois

  • The University of Chicago Medical Center - Duchossois Center for Advanced Medicine - Chicago

Ohio

  • University Hospitals Cleveland Medical Center - Cleveland

Pennsylvania

  • University of Pennsylvania - Abramson Cancer Center - Philadelphia

Tennessee

  • SCRI Oncology Partners - Nashville

Texas

  • NEXT Oncology - Austin - Austin

Henan

  • Henan Cancer Hospital - Zhengzhou

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2024-12-27
Est. Completion 2028-02-28
Phase Phase 1

Sponsor

InSilico Medicine Hong Kong Limited

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06566079

The ClinicalTrials.gov registry entry for NCT06566079 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (48% lower). The listed sponsor is InSilico Medicine Hong Kong Limited, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which ISM6331 is the first listed.

NCT06566079 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Other, Colorado, Illinois.

Frequently Asked Questions

What is clinical trial NCT06566079 about?

NCT06566079 is a clinical study titled "Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors". This is a Phase 1, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with advanced or metastatic malignant mesothelioma or other solid tumors. The study consists of two parts...

What is the current status of trial NCT06566079?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2024-12-27. Estimated completion is 2028-02-28.

What conditions does trial NCT06566079 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Malignant Mesothelioma, Metastatic Malignant Solid Tumor.

What interventions are being tested in trial NCT06566079?

The interventions under investigation include: ISM6331 (DRUG).

Who is sponsoring clinical trial NCT06566079?

This trial is sponsored by InSilico Medicine Hong Kong Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06566079 being conducted?

This trial has 10 study locations across Colorado, Illinois, Ohio, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Malignant Mesothelioma

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.